AU2795499A - Conjugated suramin or derivatives thereof with peg, polyaspartate or polyglutamate for cancer treatment - Google Patents
Conjugated suramin or derivatives thereof with peg, polyaspartate or polyglutamate for cancer treatmentInfo
- Publication number
- AU2795499A AU2795499A AU27954/99A AU2795499A AU2795499A AU 2795499 A AU2795499 A AU 2795499A AU 27954/99 A AU27954/99 A AU 27954/99A AU 2795499 A AU2795499 A AU 2795499A AU 2795499 A AU2795499 A AU 2795499A
- Authority
- AU
- Australia
- Prior art keywords
- polyaspartate
- polyglutamate
- suramin
- peg
- conjugated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B69/00—Dyes not provided for by a single group of this subclass
- C09B69/10—Polymeric dyes; Reaction products of dyes with monomers or with macromolecular compounds
- C09B69/106—Polymeric dyes; Reaction products of dyes with monomers or with macromolecular compounds containing an azo dye
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/972—Plasminogen activators
- G01N2333/9723—Urokinase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7599498P | 1998-02-26 | 1998-02-26 | |
| US60075994 | 1998-02-26 | ||
| PCT/US1999/004336 WO1999043311A2 (en) | 1998-02-26 | 1999-02-26 | Conjugated suramin or derivatives thereof with peg, polyaspartate or polyglutamate for cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2795499A true AU2795499A (en) | 1999-09-15 |
Family
ID=22129246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU27954/99A Abandoned AU2795499A (en) | 1998-02-26 | 1999-02-26 | Conjugated suramin or derivatives thereof with peg, polyaspartate or polyglutamate for cancer treatment |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2795499A (en) |
| WO (1) | WO1999043311A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1648493B1 (en) * | 2003-07-07 | 2009-12-09 | Van Andel Research Institute | Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor |
| DK1969031T3 (en) | 2005-12-05 | 2009-09-14 | Nitto Denko Corp | Polyglutamate Amino Acid Conjugates and Methods |
| BRPI0916895A2 (en) * | 2008-08-04 | 2016-02-10 | Sammy Opiyo | use of lysine, arginine and other amino compounds, product and product dosage administration |
| WO2022071204A1 (en) * | 2020-09-29 | 2022-04-07 | 日本化薬株式会社 | Polarizing element, polarizing plate and display device provided with same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR950014915B1 (en) * | 1991-06-19 | 1995-12-18 | 주식회사녹십자 | Asialoglycoprotein-conjugated compounds |
| EP0759467B1 (en) * | 1995-07-24 | 2004-02-11 | Mitsubishi Chemical Corporation | Hepatocyte growth factor activator inhibitor |
| EP0758682B1 (en) * | 1995-07-24 | 2004-05-12 | Mitsubishi Chemical Corporation | Hepatocyte growth factor activator inhibitor |
-
1999
- 1999-02-26 WO PCT/US1999/004336 patent/WO1999043311A2/en not_active Ceased
- 1999-02-26 AU AU27954/99A patent/AU2795499A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999043311A2 (en) | 1999-09-02 |
| WO1999043311A3 (en) | 1999-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL146100A0 (en) | 4,5,6,7-tetrahydroindazole derivatives as antitumor agents | |
| ZA200201511B (en) | 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents. | |
| MXPA02001497A (en) | 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents. | |
| AU2206800A (en) | Targeted molecular bar codes and methods for using the same | |
| IL139286A0 (en) | Polyol-ifn-beta conjugates, their preparation and use | |
| MXPA02001508A (en) | Arylmethylcarbonylaminothiazole derivatives and their use as antitumor agents. | |
| PT1218378E (en) | TERC-BUTYL (7-METHYL-IMIDAZO-1,2-A-PYRIDIN-3-YL) -AMINE DERIVATIVES | |
| AU2002353419A1 (en) | TGF-Beta-SPECIFIC COVALENTLY CLOSED ANTISENSE MOLECULE | |
| PL347506A1 (en) | 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | |
| AU5589999A (en) | Methods for the preparation of conjugated oligomers | |
| AU4006800A (en) | 1,2-dithiolane derivatives | |
| AU2918801A (en) | Progressive-type prize awarding scheme | |
| IL146015A0 (en) | Methods for producing 5'-nucleic acid-protein conjugates | |
| PL348668A1 (en) | 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives | |
| AU3819200A (en) | 2,4-diamino-pyrimidine derivatives | |
| HUP0103314A3 (en) | Use of camptothecin derivatives, with reduced gastrointestinal toxicity | |
| AU2795499A (en) | Conjugated suramin or derivatives thereof with peg, polyaspartate or polyglutamate for cancer treatment | |
| CA2351658A1 (en) | Anticonvulsant derivatives useful in treating post traumatic stress disorder | |
| CA2297149A1 (en) | 13-deoxyanthracycline derivatives for treating cancer | |
| AU7919100A (en) | Clear hair-treatment agent | |
| ZA993063B (en) | 2"-deoxy hygromycin derivatives. | |
| HUP0102518A3 (en) | 5-imino-13-deoxy anthracycline derivatives, their uses, and processes for preparing them | |
| GB2350361B (en) | 3,4,5-tricyanophenyl derivatives | |
| AU4598100A (en) | Treating cancer | |
| HUP0201862A2 (en) | Herbicidal tricyclic benzoylcyclohexanedione derivatives, preparation and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |